argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
26 feb 2016 - 07:06
Statutaire naam
argenx SE
Titel
argenx: Home Member State Selection
Bericht
Breda, the Netherlands/Ghent, Belgium, 26 Fabruary 2016 - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that following the implementation of the amended EU Transparency Directive (2013/50/EU), arGEN-X NV is required to publicly announce its Home Member State. In accordance with this regulation, the company announces that its Home Member State is the Netherlands.
Gerelateerde downloads
Datum laatste update: 01 september 2024